← Back to Search

Procedure

Surgical Procedure for Breast Cancer

N/A
Waitlist Available
Led By Edward I Chang
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients who have undergone treatment (mastectomy, axillary lymph node dissection [ALND], radiation and chemotherapy) for breast cancer and are seeking breast reconstruction
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Study Summary

This trial is testing how well an investigational surgery called vascularized lymph node transfer works in lowering the risk of arm swelling (lymphedema) in patients with breast cancer who are undergoing breast reconstruction.

Who is the study for?
This trial is for breast cancer patients who've had a mastectomy, lymph node removal, radiation, and chemotherapy and are now planning breast reconstruction. It's not for those pregnant or allergic to specific dyes used during surgery.Check my eligibility
What is being tested?
The study tests a new surgical method called vascularized lymph node transfer alongside breast reconstruction to see if it can reduce the risk of developing arm swelling (lymphedema) after surgery.See study design
What are the potential side effects?
Potential side effects may include complications from surgery such as infection, poor wound healing, fluid buildup in the affected limb or area where nodes were taken from, and possibly limited range of motion.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have completed treatment for breast cancer and am seeking breast reconstruction.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to lymphedema development
Secondary outcome measures
Complications of prophylactic VLNT
Incidence rate of lymphedema development

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (vascularized lymph node transfer)Experimental Treatment2 Interventions
Patients undergo vascularized lymph node transfer during standard of care breast reconstructive surgery.

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,958 Previous Clinical Trials
1,798,244 Total Patients Enrolled
148 Trials studying Breast Cancer
63,286 Patients Enrolled for Breast Cancer
National Cancer Institute (NCI)NIH
13,608 Previous Clinical Trials
40,915,308 Total Patients Enrolled
939 Trials studying Breast Cancer
1,543,333 Patients Enrolled for Breast Cancer
Edward I ChangPrincipal InvestigatorM.D. Anderson Cancer Center

Media Library

Vascularized Lymph Node Transfer (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT03990610 — N/A
Breast Cancer Research Study Groups: Treatment (vascularized lymph node transfer)
Breast Cancer Clinical Trial 2023: Vascularized Lymph Node Transfer Highlights & Side Effects. Trial Name: NCT03990610 — N/A
Vascularized Lymph Node Transfer (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03990610 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the participant capacity of this research endeavor?

"Correct. Analysis of the clinicaltrials.gov page indicates that this study, which was initially advertised on May 24th 2019, is currently enrolling participants. 25 individuals are being sought at a single medical centre."

Answered by AI

Are there any current vacancies for individuals to take part in this research?

"As indicated on clinicaltrials.gov, this experiment is presently engaging subjects and was originally uploaded on May 24th 2019. It has been revised as recently as May 4th 2022."

Answered by AI
~0 spots leftby Apr 2024